In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and survival. One important abnormality is the loss of part of chromosome 11, del(11q), which is associated ...
May 5, 2025
0
0
Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common pediatric cancers and among the leading causes of death in children.
Apr 30, 2025
0
0
Princess Margaret Cancer Center at University Health Network-led researchers constructed a detailed single-cell atlas of human blood development, improving understanding of leukemia formation and enabling a more precise classification ...
A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months earlier.
Apr 28, 2025
0
0
A ready-made version of a cutting-edge cancer immunotherapy can effectively defeat blood cancers, a new study says.
Apr 28, 2025
0
1
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their ...
Apr 23, 2025
0
0
In 2021, research led by Ryan Flynn, MD, Ph.D., and his mentor, Nobel laureate Carolyn Bertozzi, Ph.D., opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs. Extending this discovery ...
Apr 23, 2025
0
41
A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.
Apr 16, 2025
0
2
A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows. Researchers reveal explosive growth rates of cancerous cells years before ...
Apr 9, 2025
0
0
Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments. The work is published in the journal Biomarker Research.
Apr 9, 2025
0
62
